Combination Therapy for Pulmonary Arterial Hypertension (original) (raw)

Textbook of Pulmonary Vascular Disease, 2010

Abstract

Individual pharmacotherapies for pulmonary ­arterial hypertension (PAH) have significantly improved functional status, quality of life, and, in the case of epoprostenol (Epo), survival of PAH patients with the idiopathic form (IPAH), but these responses are usually partial and often temporary. In addition, these agents have potential adverse side effects and risks that may be dose-related. These limitations have stimulated interest

Ioana Preston hasn't uploaded this paper.

Let Ioana know you want this paper to be uploaded.

Ask for this paper to be uploaded.